How do you think the combination b/w SG and LL pro

Quote:

---

How do you think the combination b/w SG and LL proves out in the murine study?

Do you think the mOS is increased over SG's 11 months with the addition of LL? to LL's mOS?

---

Trodelvy binds to Trop-2 on tumor cells than delivers a topoisomerase inhibitor inside the cell that breaks the DNA. Leronlimab has some of that same activity but I think it's low level. However leronlimab has a much broader field of activity than that. Combined it's a one, two punch. Leronlimab itself has already shown to have a longer mOS than Trodelvy.

Quote:

---

If we were to triple SG's mOS from 11 months to 3 years, would that qualify for novel drug and patent extension?

---

A 3 year mOS may be overly optimistic given genetic variation but it might be possible. In order to get a new patent it would have to be a drug conjugation. I don't think that's a possibility given that Trodelvy needs to bind to Trop-2 and leronlimab needs to bind seperately to CCR5..

Quote:

---

[Let's say the offer was for somewhere what they paid for SG, but stipulated with the condition to abandon HIV, how would that go over?/quote]

If they do make a suitable buyout offer than they can do whatever they want with it.

---